The Food and Drug Administration announced on November 4, 2026, that the shortage of Clonazepam Tablets has been resolved. The drug has been listed by the FDA since March 10, 2023. Patients who rely on this medicine…
The Food and Drug Administration (FDA) is classifying the wearable vibration device for orthopedic use into class II (special controls) effective November 5, 2026. According to the FDA, this classification will provide…
The Food and Drug Administration (FDA) is classifying the prognostic assessment software of mild cognitive impairment into class II (special controls) as of November 5, 2026. According to the FDA, this classification…
On November 5, 2026, the Food and Drug Administration (FDA) announced the classification of the digital cervical cytology slide imaging system with artificial intelligence algorithm into class II (special controls)…
On November 2, 2026, the Food and Drug Administration (FDA) issued an Early Alert regarding a potential high-risk issue with ButterflyBVM Single-Use Bag-Valve-Mask Resuscitators. According to the FDA, Compact Medical…
Coral Gables, FL - Snack Right Super Foods, Inc., doing business as Brad's Raw Chips, is recalling certain Brad's Plant Based Crunchy Kale and Brad's Veggie Chips Kale products due to potential thallium contamination…
Once Upon a Farm, based in Berkeley, CA, announced on October 30, 2026, the recall of all lots and varieties of its Tractor Wheel Organic Toddler Soft-Baked bars due to a potential choking hazard. The company reported…
Right Value Drug Stores LLC announced a recall of Testosterone Cypionate, 200 mg/mL, on October 9, 2026. The recall, classified as Class II, affects products packaged in 5 mL and 30 mL vials and is due to a lack of…
On November 1, 2026, the Food and Drug Administration advised consumers not to buy or serve Once Upon a Farm Tractor Wheels Organic Toddler Soft-Baked Bars. The agency has received reports of toddlers suffering…
The Food and Drug Administration announced a recall of Levoxyl (levothyroxine sodium tablets, USP) distributed by Pfizer Inc. on September 29, 2026. The recall affects tablets in 175 mcg, 100 tablet bottles and…
On October 1, 2026, Shenzhen Techdow Pharmaceutical Co., Ltd. initiated a recall of Heparin Sodium Injection, USP, due to a lack of assurance of sterility. The recall, classified as Class II, may cause temporary or…
PRITAM INTERNATIONAL PRIVATE LIMITED has announced a recall of several toothpaste products due to cGMP deviations. The recall, classified as Class II, may cause temporary or reversible health problems and began on…
On October 1, 2026, Greenwich Rx initiated a Class I recall of its Glutathione Injection, which is classified as the most serious type of recall. The recall affects the 200 mg/mL, 10 mL multi-dose vial, which is…
Par Health USA, LLC announced a Class I recall of Argatroban Injection, USP, 250 mg/2.5mL, on October 13, 2026. The recall affects products distributed nationwide and is ongoing due to the presence of particulate…
On September 24, 2026, Philips Ultrasound, LLC initiated a Class I recall for its Lumify Diagnostic Ultrasound System. The recall affects devices distributed worldwide, including across the United States and numerous…
On September 17, 2026, Ventec Life Systems, Inc. initiated a Class I recall of several ventilatory support devices due to a potential safety issue. The recall affects devices including the VOCSN and V+ Pro Emergency…
On November 1, 2026, the Food and Drug Administration issued an Early Alert regarding a recall of the Streamline Bloodline Set for Dialog+ by B. Braun Medical Inc. The company recommended that affected customers remove…
The U.S. Food and Drug Administration issued final guidance on November 2, 2026, for manufacturers of cellular and gene therapy products to ensure their products meet potency standards. The guidance provides…
On November 2, 2026, the Food and Drug Administration proposed to amend regulations on nutrient specifications and labeling for infant formula. The proposed rule includes changes to the minimum and/or maximum levels of…
On October 30, 2026, the U.S. Food and Drug Administration granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to treat adults with recurrent respiratory…
Nothing matches. Try the search instead.
